Institute of Pharmacology, Polish Academy of Sciences, Department of Pain Pharmacology, Kraków, Poland.
Pharmacol Rep. 2018 Aug;70(4):821-830. doi: 10.1016/j.pharep.2018.01.006. Epub 2018 Feb 1.
The treatment of neuropathic pain resulting from nervous system malfunction remains a challenging problem for doctors and scientists. The lower effectiveness of conventionally used analgesics in neuropathic pain is associated with complex and not fully understood mechanisms of its development. Undoubtedly, interactions between immune and nervous system are crucial for maintenance of painful neuropathy. Nerve injury induces glial cell activation and thus enhances the production of numerous pronociceptive factors by these cells, including interleukins and chemokines. Increased release of those factors reduces the analgesic efficacy of opioids, which is significantly lower in neuropathic pain than in other painful conditions. This review discusses the role of chemokines from all four subfamilies as essential mediators of neuron-glia interactions occurring under neuropathic pain conditions. Based on available data, we analyse the influence of chemokines on opioid properties. Finally, we identify new direct and indirect pharmacological targets whose modulation may result in effective therapy of neuropathic pain, possibly in combination with opioids.
神经功能障碍引起的神经性疼痛的治疗仍然是医生和科学家面临的一个挑战。传统使用的镇痛药在神经性疼痛中效果较低,这与其复杂且尚未完全理解的发病机制有关。毫无疑问,免疫和神经系统之间的相互作用对于维持疼痛性神经病至关重要。神经损伤会诱导神经胶质细胞激活,从而增强这些细胞产生许多致痛因子的能力,包括白细胞介素和趋化因子。这些因子的释放增加会降低阿片类药物的镇痛效果,而在神经性疼痛中的效果明显低于其他疼痛情况。本综述讨论了所有四个亚家族的趋化因子作为在神经性疼痛条件下发生的神经元-神经胶质相互作用的基本介质的作用。根据现有数据,我们分析了趋化因子对阿片类药物特性的影响。最后,我们确定了新的直接和间接的药理学靶点,其调节可能导致神经性疼痛的有效治疗,可能与阿片类药物联合使用。